PYXS pyxisoncology.com: Enterprise Value to EBITDA Ratio

Graphic logo of Pyxis Oncology (PYXS)

Pyxis Oncology, Inc. (PYXS) develops unique targeted antibodies, which shields the company from price wars with mass-market drug manufacturers. The company relies on several innovative platforms, minimizing the risk of a single project failure. The confirmed price history on the GURU.Markets chart reflects an EV/EBITDA value of 0.00. High profitability is driven by precision cold-chain logistics and partnerships with a network of contract laboratories.

Pyxis Oncology Inc. - PYXS Total Company Value to Operating Income Before Depreciation Ratio (period 11/23/2025 - 11/12/2026)

Summary analytical data breakdowns for pyxisoncology.com (PYXS)

- stock price and consensus target price:
Stock Quotes Pyxis Oncology|PYXS - Average Forecast Price
- company stock capitalization data:
Market Valuation Pyxis Oncology, Inc.|PYXS - Value Adjusted for Debt and Cash
- business book valuation details:
Book Value per Share Pyxis Oncology|PYXS - Book Valuation of Business|Market Value to Book Value Ratio pyxisoncology.com|PYXS - Cumulative Company Assets
- debt and solvency information:
Debt to Equity Pyxis Oncology, Inc.|PYXS - Long-Term Debt to Equity Ratio|Short-Term Debt to Equity Ratio Pyxis Oncology|PYXS - Company Aggregate Debts|Debt to Book Capitalization Ratio Pyxis Oncology, Inc.|PYXS - Company Long-Term Indebtedness|Company Short-Term Debt Pyxis Oncology|Quick Liquidity Indicator pyxisoncology.com
- financial results and valuation multiples details:
PYXS - Annual Net Income|Future Profit Pyxis Oncology, Inc.|PYXS - Market Price to Net Income Ratio|Forward P/E Multiple Pyxis Oncology|PYXS - Growth-Adjusted Payback Ratio|EV/EBITDA Multiple Pyxis Oncology, Inc.|PYXS - Profit before interest, taxes and amortization|Earnings per share for the last twelve months Pyxis Oncology|PYXS - Earnings per share for the trailing year|Quarterly EPS earnings growth pyxisoncology.com|PYXS - Earnings growth in current year|Net earnings per share growth forecast for next year Pyxis Oncology, Inc.
Fundamental company analysis:PYXS (Pyxis)
Original product of Pyxis Oncology Inc.

The EV/EBITDA ratio compares the total enterprise value of a business, including net debt, with its operating profit before taxes and amortization. A decline in this metric signals that an asset is undervalued, whereas an increase may indicate overbought conditions or a heavy debt load. By analyzing the historical EV/EBITDA levels of a company, an investor assesses the efficiency of capital management. For Pyxis Oncology, Inc. (PYXS), this indicator is critical in establishing a future monopoly within the targeted cancer therapy market.

Competitor analysis for Pyxis Oncology, Inc.

ImmunityBio Corp - Enterprise Value to EBITDA Ratio|Immunocore Corp (IMCR) - Company Value to EBITDA|JANX: Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation RCUS (arcusbio.com)|ZYME: EV/EBITDA Multiple|TNGX - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Iovance|Enterprise Value to EBITDA Ratio Immatics Biotechnologies (IMTX)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Xencor, Inc. (XNCR)|Enterprise Value to EBITDA Ratio compasstherapeutics.com CMPX|Replimune - Enterprise Value to EBITDA Ratio|EV/EBITDA Multiple Lyell LYEL|IPHA - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|CGEN (Compugen Ltd.) - Enterprise Value to Operating Income Before Depreciation|IO Biotech, Inc. (IOBT) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA sutrobio.com (STRO)|Enterprise Value to EBITDA Ratio INKT|HOWL - Enterprise Value to EBITDA Multiple|Enterprise Value to EBITDA Ratio IMMX (Immix Biopharma, Inc.)|Enterprise Value to Operating Income Before Depreciation Ratio ALXO|EV/EBITDA Multiple CUE (Cue Biopharma)|Business Value to Operating Income Before Depreciation PDSB|Sonnet BioTherapeutics Holdings Inc. - EV/EBITDA Multiple|Company Value to EBITDA MAIA Biotech|Liminatus Pharma Corp (LIMN) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|LAVA Therapeutics - Business Value to Operating Income Before Depreciation|NXTC (NextCure, Inc.) - EV/EBITDA Multiple|EV/EBITDA Multiple Leap Tx|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Intensity Therapeutics (INTS)|SNSE: Company Value to Operating Income Before Depreciation Ratio|Synthetic Biologics - Enterprise Value to EBITDA Ratio|Gritstone bio Inc. (GRTS) - Company Value to EBITDA|KA - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to Operating Income Before Depreciation Ratio NEXI|TSBX (turnstonebio.com) - Enterprise Value to EBITDA Ratio|Company Value to EBITDA Vaccinex Inc. (VCNX)|Enterprise Value to EBITDA Ratio HARP